| Bioactivity | AWL-II-38.3 is a potent ephrin-A receptor (EphA3) kinase inhibitor. AWL-II-38.3 does not exhibit significant cellular activity against Src-family kinases nor against b-raf[1][2][1][2]. | ||||||||||||
| Target | Ephrin-A receptor (EphA3) kinase | ||||||||||||
| Invitro | AWL-II-38.3 fits to LIMK2 and LIMK1 ATP-binding and substrate-binding pockets[2]. | ||||||||||||
| Name | AWL-II-38.3 | ||||||||||||
| CAS | 1135205-94-5 | ||||||||||||
| Formula | C23H18F3N5O3 | ||||||||||||
| Molar Mass | 469.42 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Yongmun Choi, et al. Discovery and structural analysis of Eph receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2009 Aug 1;19(15):4467-70. [2]. Efrat Mashiach-Farkash, et al. Computer-based identification of a novel LIMK1/2 inhibitor that synergizes with salirasib to destabilize the actin cytoskeleton. Oncotarget. 2012 Jun;3(6):629-39. |
AWL-II-38.3
CAS: 1135205-94-5 F: C23H18F3N5O3 W: 469.42
AWL-II-38.3 is a potent ephrin-A receptor (EphA3) kinase inhibitor. AWL-II-38.3 does not exhibit significant cellular ac
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.